SunBio, Inc. Logo

SunBio, Inc.

Develops biopharmaceuticals and devices like artificial blood using proprietary PEGylation technology.

067370 | KO

Overview

Corporate Details

ISIN(s):
KR7067370007
LEI:
Country:
South Korea
Address:
인천광역시 남동구 은봉로 129 -, 인천광역시
Sector:
Manufacturing
Industry:
Manufacture of pharmaceuticals, medicinal chemical and botanical products

Description

SunBio, Inc. is a biotechnology company that develops, produces, and commercializes biosimilars, biopharmaceuticals, and medical devices. The company's core research and development activities are based on its proprietary PEGylation technology, a platform used to enhance the efficacy and duration of therapeutic drugs. Key products in its pipeline include an artificial blood substitute and MucoPEG, a treatment for xerostomia (dry mouth).

Unlock This Filing & Millions More

You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.

Filings

You have of free filing views remaining. Upgrade for unlimited access.
Quick Filters:

Filters

Clear
Bulk Actions:
Date Filing Language Size Actions
2025-08-14 00:00
Interim Report
반기보고서 (2025.06)
Korean 1.1 MB
2025-06-26 00:00
Transaction in Own Shares
자기주식취득결과보고서
Korean 61.5 KB
2025-05-15 00:00
Quarterly Report
분기보고서 (2025.03)
Korean 1.1 MB
2025-04-07 00:00
Share Issue/Capital Change
전환가액의조정 (제4회차)
Korean 10.7 KB
2025-03-31 00:00
Post-Annual General Meeting Information
정기주주총회결과
Korean 21.5 KB
2025-03-31 00:00
Regulatory News Service
본점소재지변경
Korean 5.8 KB
2025-03-31 00:00
Board/Management Information
사외이사의선임ㆍ해임또는중도퇴임에관한신고
Korean 9.9 KB
2025-03-24 00:00
Transaction in Own Shares
주요사항보고서(자기주식취득신탁계약체결결정)
Korean 33.8 KB
2025-03-21 00:00
Audit Report / Information
사업보고서 (2024.12)
Korean 353.1 KB
2025-03-21 00:00
Annual Report
[기재정정]사업보고서 (2024.12)
Korean 1.3 MB
2025-03-14 00:00
Pre-Annual General Meeting Information
주주총회소집공고
Korean 94.4 KB
2025-03-12 00:00
Audit Report / Information
감사보고서제출
Korean 18.8 KB
2025-03-06 00:00
Pre-Annual General Meeting Information
주주총회소집결의
Korean 10.0 KB
2025-02-12 00:00
Earnings Release
매출액또는손익구조30%(대규모법인은15%)이상변동
Korean 11.4 KB
2024-12-11 00:00
Pre-Annual General Meeting Information
주주명부폐쇄기간또는기준일설정
Korean 4.5 KB

Automate Your Workflow. Get a real-time feed of all SunBio, Inc. filings delivered via API.

Explore Data Feeds →

Market Data

Market Data Not Available

Financials & KPIs

No data available

Unlock Full Financials for SunBio, Inc.

This data is available as part of our premium data solutions. Contact our team for access.

Need More History? Access decades of standardized financials for SunBio, Inc. via our API.

Get Historical Data →

Insider Transactions

Date Insider Name Position Type Shares Value
No insider transactions recorded for this company.

Peer Companies

ArcticZymes Technologies Logo
Develops novel enzymes from Arctic organisms for diagnostics, therapeutics, and biopharma.
Norway
AZT
Arcturus Therapeutics Holdings Inc. Logo
Develops mRNA therapeutics and vaccines for rare respiratory, liver, and infectious diseases.
United States of America
ARCT
Arcus Biosciences, Inc. Logo
A clinical-stage biopharma developing small molecule and antibody combination therapies for cancer.
United States of America
RCUS
Arcutis Biotherapeutics, Inc. Logo
Develops and commercializes non-steroidal therapies for immune-mediated skin diseases.
United States of America
ARQT
ARDELYX, INC. Logo
Biopharma developing first-in-class drugs for cardiorenal and GI diseases like IBS-C and CKD.
United States of America
ARDX
ARECOR THERAPEUTICS PLC Logo
Biopharma firm enhancing drugs via reformulation for diabetes and pharmaceutical partners.
United Kingdom
AREC
argenx SE Logo
Develops first-in-class antibody therapies for severe autoimmune diseases.
Netherlands
1AE
Armata Pharmaceuticals, Inc. Logo
Developing bacteriophage therapeutics for antibiotic-resistant infections.
United States of America
ARMP
AroCell AB Logo
Develops and markets diagnostic tests for monitoring cancer and bacterial diseases.
Sweden
AROC
ArriVent BioPharma, Inc. Logo
A clinical-stage biopharma developing in-licensed oncology drugs for difficult-to-treat diseases.
United States of America
AVBP

Talk to a Data Expert

Have a question? We'll get back to you promptly.